Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

SIMPLE SUMMARY: Cytokine release syndrome is a potentially life-threatening complication of therapy with T-cell engaging bispecific antibodies. Here we evaluated the risk, characteristics and biomarkers of treatment-emergent cytokine release syndrome in patients with relapsed/refractory acute myeloi...

Descripción completa

Detalles Bibliográficos
Autores principales: Uckun, Fatih M., Watts, Justin, Mims, Alice S., Patel, Prapti, Wang, Eunice, Shami, Paul J., Cull, Elizabeth, Lee, Cynthia, Cogle, Christopher R., Lin, Tara L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582601/
https://www.ncbi.nlm.nih.gov/pubmed/34771451
http://dx.doi.org/10.3390/cancers13215287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582601/
https://www.ncbi.nlm.nih.gov/pubmed/34771451
http://dx.doi.org/10.3390/cancers13215287

Ejemplares similares